Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes

Pharmacogenetics and Genomics

Volumn 15, Issue 11, 2005, Pages 769-778

  Lazarus, Philip ^a   Zheng, Yan ^a   Runkle, E Aaron ^a   Muscat, Joshua E ^a   Wiener, Doris ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Genotype:phenotype correlation; NNK; Polymorphism; Tobacco specific nitrosamine; UDP glucuronosyltransferase; UGT2B17

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; GLUCOSE; GLUCURONIDE;

ALLELE; ARTICLE; BIOASSAY; CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DETOXIFICATION; ENZYME ACTIVITY; GENE DELETION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; REDUCTION; STATISTICAL ANALYSIS; TOBACCO;

NICOTIANA TABACUM;

EID: 27444436445     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000175596.52443.ef     Document Type: Article

References (36)

1. Hecht SS, Hoffmann D. The relevence of tobacco-specific nitrosamines to human cancer. Cancer Surv 1989; 8:273-294.
2. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific nitrosamines. Chem Res Toxicol 1998; 11:559-603.
3. Adams JD, O'Mara-Adams KJ, Hoffmann D. Toxic and carcinogenic agents in undiluted mainstream smoke and sidestream smoke of different types of cigarettes. Carcinogenesis 1987; 8:729-731.
4. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived N-nitrosamines. Cancer Res 1988; 48:6912-6917.
5. Hecht SS, Rivenson A, Braley J, DiBello J, Adams JD, Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res 1986; 46:4162-4166.
6. Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot RR. Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone. Cancer Res 1990; 50:3772-3780.
7. Carmella SG, Akerkar SA, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers urine. Cancer Res 1993; 53:721-724.
8. Hecht SS, Trushin N, Reid-Quinn CA, Burak ES, Jones AB, Southers JL, et al. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in the Patas monkey: pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis 1993; 14: 229-236.
9. Morse MA, Eklind KI, Toussaint M, Amin SG, Chung FL. Characterization of a glucuronide metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butone (NNK) and its dose-dependent excretion in the urine of mice and rats. Carcinogenesis 1990; 11:1819-1823.
10. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Disp 2000; 28:1352-1360.
11. Hecht SS, Carmella SG, Chen M, Koch JFD, Miller AT, Murphy SE, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999; 59:590-596.
12. Upadhyaya P, Kenny RJ, Wang M, Hecht SS. Tumorigenicity and metabolism of (NNAL) enantiomers and metabolites in A/J mice. Carcinogenesis 1999; 15:1577-1582.
13. Upadhyaya P, Carmella AG, Guengerich FP, Hecht SS. Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues. Carcinogenesis 2000; 21: 1233-1238.
14. Kim PM, Wells PG. Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Cancer Res 1996; 56:1526-1532.
15. Carmella SG, Upadhyaya P, Hecht SS. Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 2002; 15:545-550.
16. Wiener D, Fang J-L, Doerge D, Upadhyaya P, Tephly T, Lazarus P. UDP-glucuronosyltransferase 1A4: N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Drug Metabol Disp 2003; 32:72-79.
17. Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995; 4:635-642.
18. Wiener D, Fang J-L, Dosett N, Lazarus P. Correlation between UDP-glucuronosyl-transferase genotypes and NNAL glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64:1190-1196.
19. Beaulieu M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem 1996; 271:22855-22862.
20. Turgeon D, Carrier J-S, Chouinard S, Belanger A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metabol Disp 2003; 31:670-676.
21. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3:136-158.
22. Ritter JK, Sheen YY, Owens IS. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. J Biol Chem 1990; 265: 7900-7906.
23. Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. Pharmacol Exp Ther 1993; 264:475-479.
24. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15 (Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7:317-325.
25. Levesque E, Beaulieu M, Hum DW, Belanger A. Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1999; 9:207-216.
26. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197:1279-1289.
27. Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-714.
28. Coughtrie MWH, Burchell B, Bend JR. Purification and properties of rat kidney UDP-glucuronyltransferase. Biochem Pharmacol 1987; 36: 245-251.
29. Pritchard M, Fournel-Gigleux S, Siest G, Mackenzie P, Magdalou J. A recombinant phenobarbitol-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids. Mol Pharmacol 1994; 45:42-50.
30. Ren Q, Murphy SE, Dannenberg AJ, Park JY, Tephly TR, Lazarus P. Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (NNAL) by rat UDP-glucuronosyltransferase 2B1. Drug Metabol Disp 1999; 27:1010-1016.
31. Zheng Z, Fang J-L, Lazarus P. Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metabol Disp 2002; 30:397-403.
32. Tephly TR, Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990; 11:276-279.
33. Richie JP, Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1 -butanone (NNK) in black and white smokers. Cancer Epidemiol Biomarkers Prev 1997; 6: 783-790.
34. Hecht SS, Carmella SG, Murphy SE, Akerker SA, Brunnemann KD, Hoffman D. Metabolites of a tobacco-specific lung carcinogen in the urine of non-smokers exposed to tobacco smoke. New Engl J Med 1994; 329: 1543-1546.
35. Parsons WD, Carmella SG, Akerkar S, Bonilla LE, Hecht SS. A metabolite of the tobacco-specific lung carcinogen 4 (methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in the urine of hospital workers exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers Prev 1998; 7:257-260.
36. Murphy SE, Carmella SG, Idris AM, Hoffmann D. Uptake and metabolism of carcinogenic levels of tobacco specific nitrosamines by Sudanese snuff dippers. Cancer Epidemiol Biomarkers Prev, 1994; 3:423-428.